Gain Therapeutics Inc (NASDAQ: GANX)’s stock price has soared by 4.68 in relation to previous closing price of 1.71. globenewswire.com reported 2025-06-10 that BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences: H.C.
Is It Worth Investing in Gain Therapeutics Inc (NASDAQ: GANX) Right Now?
The 36-month beta value for GANX is also noteworthy at 0.11. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GANX is 28.48M, and at present, short sellers hold a 1.02% of that float. The average trading volume of GANX on June 19, 2025 was 266.34K shares.
GANX’s Market Performance
GANX’s stock has seen a 0.00% decrease for the week, with a -8.67% drop in the past month and a -27.53% fall in the past quarter. The volatility ratio for the week is 3.65%, and the volatility levels for the past 30 days are at 3.49% for Gain Therapeutics Inc The simple moving average for the last 20 days is -2.28% for GANX’s stock, with a simple moving average of -8.97% for the last 200 days.
Analysts’ Opinion of GANX
Many brokerage firms have already submitted their reports for GANX stocks, with Scotiabank repeating the rating for GANX by listing it as a “Sector Outperform.” The predicted price for GANX in the upcoming period, according to Scotiabank is $12 based on the research report published on March 07, 2025 of the current year 2025.
ROTH MKM, on the other hand, stated in their research note that they expect to see GANX reach a price target of $7. The rating they have provided for GANX stocks is “Buy” according to the report published on December 06th, 2024.
Oppenheimer gave a rating of “Outperform” to GANX, setting the target price at $8 in the report published on August 14th of the previous year.
GANX Trading at -3.63% from the 50-Day Moving Average
After a stumble in the market that brought GANX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.89% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GANX starting from Mack Gene, who purchase 14,400 shares at the price of $1.01 back on Aug 09 ’24. After this action, Mack Gene now owns 14,400 shares of Gain Therapeutics Inc, valued at $14,544 using the latest closing price.
Islam Khalid, the Executive Chairman of Gain Therapeutics Inc, purchase 50,000 shares at $1.00 during a trade that took place back on Aug 09 ’24, which means that Islam Khalid is holding 50,000 shares at $49,940 based on the most recent closing price.
Stock Fundamentals for GANX
The total capital return value is set at -3.08. Equity return is now at value -290.21, with -159.74 for asset returns.
Based on Gain Therapeutics Inc (GANX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -85.28.
Currently, EBITDA for the company is -19.79 million with net debt to EBITDA at 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.22.
Conclusion
In summary, Gain Therapeutics Inc (GANX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
